Correction: Methodology of the SORENTO clinical trial: a prospective, randomised, active-controlled phase 3 trial assessing the efficacy and safety of high exposure octreotide subcutaneous depot (CAM2029) in patients with GEP-NET

• Simron Singh,
• Diego Ferone,
• Jaume Capdevila,
• Jennifer Ang Chan,
• Wouter W. de Herder,
• Daniel Halperin,
• Josh Mailman,
• Lisa Hellström,
• Hanna Liedman,
• Agneta Svedberg,
• Fredrik Tiberg

Affiliations

Simron Singh

Sunnybrook Health Sciences Center

Diego Ferone

Endocrinology, Department of Internal Medicine & Medical Specialties, University of Genova, Endocrinology Clinic IRCCS Ospedale Policlinico San Martino

Jaume Capdevila

Vall d’Hebron University Hospital

Jennifer Ang Chan

Dana-Farber Cancer Institute

Wouter W. de Herder

Erasmus MC & Erasmus MC Cancer Institute

Daniel Halperin

The University of Texas MD Anderson Cancer Center

Josh Mailman

Northern California CarciNET Community

Lisa Hellström

Camurus AB

Hanna Liedman

Camurus AB

Agneta Svedberg

Camurus AB

Fredrik Tiberg

Camurus AB